Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib and Local Ablative Therapy in Oligoprogressive EGFR-mutated NSCLC
NCT02759835Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2016
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Apr 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02759835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02759835.